Search

Displaying results 9571 - 9580 of 9699 in total
  1. Drug

    Zavegepant

    go.drugbank.com/drugs/DB15688
    ApprovedInvestigational

    Zavegepant (BHV-3500) is a calcitonin gene-related peptide (CGRP) receptor antagonist. … [L45505] CGRP is released from sensory nerves and acts as a strong vasodilator, and thanks to these properties, it is involved in pain pathways.

  2. Drug

    Sulfamethylthiazole

    go.drugbank.com/drugs/DB15882
    Experimental

    Sulfamethylthiazole is a sulfonamide antibacterial agent.[A275183]

  3. Drug

    Sulfametrole

    go.drugbank.com/drugs/DB15975
    Investigational

  4. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor … [A262566] Factor B is a positive regulator of the alternative complement pathway, where it activates C3 convertase and subsequently C5 convertase.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). … [L45758] APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and elevating susceptibility to infections

  6. Drug

    Odevixibat

    go.drugbank.com/drugs/DB16261
    ApprovedInvestigational

    [L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid].

  7. Drug

    Orelabrutinib

    go.drugbank.com/drugs/DB16272
    Investigational

    Orelabrutinib is under investigation in clinical trial NCT04305197 (A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)).

  8. Drug

    Veliflapon

    go.drugbank.com/drugs/DB16346
    Investigational

    Veliflapon is under investigation in clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina).

  9. Drug

    Deoxyribonuclease I

    go.drugbank.com/drugs/DB16523
    Investigational

    Deoxyribonuclease I (DNase I) is a human enzyme responsible for the digestion of extracellular DNA7[A227723]. It is normally found in saliva, urine, pancreatic secretions, and blood[A227723]. … Because of the hypothesis that increased concentrations of high-molecular-weight DNA is a factor for airway obstruction, abnormal viscoelastic properties of the sputum, and recurrent exacerbations of respiratory

  10. Drug

    Deucravacitinib

    go.drugbank.com/drugs/DB16650
    ApprovedInvestigational

    Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. … [A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered